Treatment Toxicities in Long-Term Survivors of Limited Small Cell Lung Cancer
| Autor: | James R. Jett, E. G. Shaw, J. N. Shaw, R. L. Richardson, Coles Dt, Eagan Rt, Creagan Et, Lee Re, S. Frytak |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Vincristine Lung Neoplasms Cyclophosphamide medicine.medical_treatment Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Combined Modality Therapy Carcinoma Small Cell Etoposide Chemotherapy Radiotherapy business.industry Brain General Medicine Lomustine Surgery Radiation therapy Prophylactic cranial irradiation business medicine.drug |
| Zdroj: | Cancer Investigation. 6:669-676 |
| ISSN: | 1532-4192 0735-7907 |
| DOI: | 10.3109/07357908809078033 |
| Popis: | A total of 211 patients with limited small cell lung cancer were assessed retrospectively for long-term toxicities, treatment-related deaths, and second primaries. All had received treatment with various combinations of doxorubicin, vincristine, cisplatin, lomustine, cyclophosphamide, and etoposide with or without split-course thoracic radiotherapy (4,000 cGy/10 fractions) and/or split-course prophylactic cranial irradiation (3,600 cGy/10 fractions). Sixty-eight (32%) of the patients survived longer than 1.5 years and formed the basis of this study. Debilitating pulmonary, cardiac, and neurologic toxicity was noted in 12%, 14%, and 15%, respectively, of long-term survivors. These complications were the result of aggressive combined modality therapy. Certain drugs appeared to cause additive toxicity when combined with radiation. Three patients developed new primary tumors of squamous cell origin. Attention must be directed to defining the safest way to employ aggressive combined modality treatment for these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|